These new joint MASCC-ASCO standards and recommendations were developed to address existing gaps and to help promote clinical care, research, and policy specifically targeting the growing population of people affected by advanced or metastatic cancer.
Doctors Vamsi Velcheti, Sandip Patel, and Michael Zervos discuss recent updates on the management of early-stage non-small cell lung cancer (NSCLC), including the optimization of neoadjuvant and adjuvant treatment options for patients and the role of surgery in the era of targeted therapy and immuno-oncology in lung cancer.
Cancer cachexia-anorexia is a major clinical problem. Investigational new drugs, mainly aimed at the regulation of appetite and satiety in the hypothalamus/brainstem, are in development to address this critical issue.
Luspatercept is now the standard first-line treatment for anemia in lower-risk MDS. Although COMMANDS established the benefit of luspatercept over ESAs in transfusion-dependent lower-risk MDS with ring-sideroblasts or SF3B1 mutations, further studies on those with non-ring-sideroblasts and non–SF3B1-mutant disease are needed.
ARSIs are widely used across the spectrum of advanced prostate cancers, and evidence suggests they may be associated with an increased risk of depression and cognitive impairment. Knowing differing effects of the ARSIs on mental health and cognition could be critical in treatment selection.
The gynecologic cancer field has seen an increase in the number of novel therapeutics, resulting in clinically meaningful improvements for patients across a range of diseases. An Education Session will highlight these updates and how best to incorporate them into practice.
A Case-Based Panel Session during the 2024 ASCO Annual Meeting will explore what it will take for multicancer detection tests to be ready for prime time, how that could look, and how to have conversations about them with patients.
Cancer Cachexia: Pragmatic Solutions and Investigational New Drugs on the Horizon
Upfront Therapy for Anemia in Lower-Risk Myelodysplastic Syndromes: Luspatercept for All or for Some?
Mental Health and Cognitive Toxicities of Androgen Receptor Signaling Inhibitors